Satellos Bioscience Inc., a clinical-stage biotech company, announced its management will present at two investor conferences in June: the Jefferies Global Healthcare Conference on June 4 in New York and the Oppenheimer CNS & Neuro-Muscular Summit on June 10 in Miami. The company is developing SAT-3247, an oral drug aimed at treating degenerative muscle diseases like Duchenne muscular dystrophy (DMD) by targeting muscle repair processes. Presentations will be webcast live, and leadership will hold one-on-one investor meetings. This engagement highlights Satellos' ongoing clinical progress and plans to expand its therapeutic applications.
Oil prices are rising sharply due to renewed US naval blockades on Iranian shipping and increased tensions in the Strait of Hormuz, a critical oil transit route. Brent crude is holding above $85 and WTI above $80, with forecasts suggesting WTI could ...
The US government announced it will impose a new 25% tariff on Brazilian ethanol starting next Wednesday, accusing Brazil of unfair trade practices. This tariff excludes major Brazilian exports like oil, beef, coffee, and aircraft parts. The move fol...
Alibaba and Baidu shares rose after Apple received approval from China's Cyberspace Administration to include Apple Intelligence, integrating Alibaba's Qwen AI model and Baidu's AI features into Apple devices in China. This partnership allows users t...
Ondo Finance has introduced the first tokenized stock representations backed by DTCC tokenized entitlements, joining major financial firms in a significant tokenization initiative. This move highlights Ondo's unique position in building infrastructur...
Leading Japanese companies, startups, and research institutions are developing specialized AI models using NVIDIA Nemotron open models to address Japan's unique language, industrial, and workforce challenges. These AI applications range from enterpri...
